Comparison of efficacy of Levetiracetam with Sodium Valproate in the treatment of Chronic Migraine Headache

Comparison of efficacy of Levetiracetam with Sodium Valproate in the treatment of Chronic Migraine Headache in patients referred to Ahvaz Golestan Hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015022812781N2

Enrollment

Registered

2015-03-12

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine. Condition 2: Migraine. Migraine without aura [common migraine] Migraine with aura [classical migraine]

Interventions

Intervention 1: Intervention:Levebel 500-1000 mg Oral Twice daily for 3 months. Intervention 2: Control: Depakine 500-1000 mg Oral Twice daily for 3 months.

Treatment - Drugs

Intervention:Levebel 500-1000 mg Oral Twice daily for 3 months

Control: Depakine 500-1000 mg Oral Twice daily for 3 months

Eligibility

Sex/Gender

All

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic migraine headache according to the International Headache Society criteria , (having headache 15 or more days per month with at least 8 days per month fulfilling International Headache Society criteria for migraine for at least 3 months) in the absence of ongoing medication overuse; Women have a negative pregnancy test and have appropriate contraception during the study period; No history of liver disease and kidney; No headaches other than migraine-like headaches included tension headache,sinus headache disorder,structural or post traumatic headache and Exclusion criteria: The incidence of side effects such as gastrointestinal or any other unwanted side effects caused by drug; Do not use the medication in groups for three consecutive days or a week of intermittent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
MIDAS Score. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Based on a standard questionnaire MIDAS.;Intensity of headache. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Pain severity grading scale by the patient with headache severity from grade 0 to 10.;Frequency of headache. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Headache days per month.	—

Measure

Time frame

MIDAS Score. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Based on a standard questionnaire MIDAS.;Intensity of headache. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Pain severity grading scale by the patient with headache severity from grade 0 to 10.;Frequency of headache. Timepoint: 1 and 3 months after starting treatment. Method of measurement: Headache days per month.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrnoush Siavashi

Ahvaz Golestan Hospital

shoonrhem@yahoo.com+98 61 3374 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026